AcelRx Pharmaceuticals (ACRX) Receives Average Recommendation of “Hold” from Brokerages

AcelRx Pharmaceuticals (NASDAQ:ACRX) has been assigned an average rating of “Hold” from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $5.00.

Separately, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a report on Wednesday, December 27th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ACRX traded up $0.20 during trading on Wednesday, reaching $2.45. 607,998 shares of the company traded hands, compared to its average volume of 430,128. The company has a quick ratio of 4.57, a current ratio of 4.64 and a debt-to-equity ratio of -0.31. The company has a market cap of $114.52, a PE ratio of -2.14 and a beta of 2.41. AcelRx Pharmaceuticals has a 52-week low of $1.55 and a 52-week high of $5.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). The company had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $2.90 million. equities research analysts anticipate that AcelRx Pharmaceuticals will post -0.98 EPS for the current fiscal year.

A hedge fund recently bought a new stake in AcelRx Pharmaceuticals stock. Virtu Financial LLC acquired a new position in AcelRx Pharmaceuticals (NASDAQ:ACRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 59,184 shares of the specialty pharmaceutical company’s stock, valued at approximately $120,000. Virtu Financial LLC owned about 0.12% of AcelRx Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 9.20% of the company’s stock.

WARNING: “AcelRx Pharmaceuticals (ACRX) Receives Average Recommendation of “Hold” from Brokerages” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/04/16/acelrx-pharmaceuticals-acrx-receives-average-recommendation-of-hold-from-brokerages.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply